IP Library › Granted Patent US 12,709,634
Granted Patent B2
US 12,709,634 · App. 17/779,564 · Granted Aug 18, 2026

Treatment of diseases related to hepatitis B virus

Inventors: Sonja Ingrid Buschow (Utrecht, NL); Monica Theodora Antonetta de Beijer (Rotterdam, NL); Miranda Bernardina Johanna Molenaar (Maarssen, NL); Thomas Johannes Maria Beenakker (Leiden, NL); Wilhelmus Johannes Theodorus Alexander Krebber (Leiden, NL); Cornelis Johannes Maria Melief (Haarlem, NL); Anna-Sophia Wiekmeijer (Oegstgeest, NL); Peter van Rijn (Leiden, NL); Diahann Talia Satirah Ludovica Jansen (Leiden, NL); Wilhelmus Johannes Elizabeth van Esch (Purmerend, NL)
Assignees: ISABELLA PHARMA B.V.; ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
C07K14/005A61K39/292A61P31/20A61K2039/51C12N2730/10121C12N2730/10134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,709,634
App. No.
17/779,564
Filed
May 25, 2022
Granted
Aug 18, 2026
Kind
B2
Art Unit
1672
USPC
424/186.1
Abstract

The invention provides novel immunogenic peptides derived from the X protein and polymerase protein of hepatitis B virus (HBV). The peptides contain epitopes that are well-conserved across multiple HBV variants and are derived from regions of proteins that are essential for viral replication. Moreover, the novel HBV antigens bind multiple HLA types and epitopes that elicit IFNγ responses in PBMCs from HBV resolvers have been identified.

Claims (9)

1 . An immunogenic composition comprising:

a peptide comprising a fragment of an HBV protein, wherein said fragment is no more than 34 amino acids in length and wherein said fragment comprises or consists of a sequence selected from the group consisting of: SEQ ID NO:31 (SLP1), SEQ ID NO:32 (SLP2), SEQ ID NO:34 (SLP4) and SEQ ID NO:35 (SLP5),

a pharmaceutically-acceptable carrier.

2 . The immunogenic composition according to claim 1 , wherein the composition further comprises an adjuvant.

3 . The immunogenic composition according to claim 2 , wherein the adjuvant is an immune potentiating adjuvant.

4 . The immunogenic composition according to claim 1 , wherein the peptide consists of the sequence set forth in SEQ ID NO:31 (SLP1).

5 . The immunogenic composition according to claim 1 , wherein the peptide consists of the sequence set forth in SEQ ID NO:32 (SLP2).

6 . The immunogenic composition according to claim 1 , wherein the peptide consists of the sequence set forth in SEQ ID NO:34 (SLP4).

7 . The immunogenic composition according to claim 1 , wherein the peptide consists of the sequence set forth in SEQ ID NO:35 (SLP5).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2025
From: ISA PHARMACEUTICALS B.V.
To: ISABELLA PHARMA B.V.
Reel/Frame 071135/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2022
From: BUSCHOW, SONJA INGRID; DE BEIJER, MONICA THEODORA ANTONETTA; MOLENAAR, MIRANDA BERNARDINA JOHANNA; BEENAKKER, THOMAS JOHANNES MARIA; KREBBER, WILHELMUS JOHANNES THEODORUS ALEXANDER; MELIEF, CORNELIS JOHANNES MARIA; WIEKMEIJER, ANNA-SOPHIA; VAN RIJN, PETER; JANSEN, DIAHANN TALIA SATIRAH LUDOVICA; VAN ESCH, WILHELMUS JOHANNES ELISABETH
To: ISA PHARMACEUTICALS B.V.; ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 061847/0561 →
Priority Claims (1)
EP 19214315 · Dec 7, 2019 · regional
Continuity (1)
Related Publication 20230242590A1 · Aug 3, 2023
References Cited (17)
US 6689363B1 · Sette · 2004 [cited by examiner]
US 9340577B2 · Grey · 2016 [cited by examiner]
US 10300132B2 · Georges · 2019 [cited by examiner]
US 10898567B2 · Krebber · 2021 [cited by examiner]
US 20060051746A1 · Chisari · 2006 [cited by applicant]
CN 108239657A · 2018 [cited by applicant]
JP 2022534243A · 2022 [cited by applicant]
WO 9821317A1 · 1998 [cited by applicant]
WO 0219986A1 · 2002 [cited by applicant]
WO 2007110098A1 · 2007 [cited by applicant]
WO 2014102540A1 · 2014 [cited by applicant]
WO 2015187009A1 · 2015 [cited by applicant]
Kadowaki M. et al., “Immunochemical study on hepatitis B virus (HBV) gene products with use of synthetic peptides—chemical synthesis of HBVx-related peptides,” 1985. [cited by applicant]
KR Office Action dated Sep. 23, 2025 as received in Application No. 10-2022-7023156. [cited by applicant]
Malmassari, S. et al: In vivo hierarchy of immunodominant and subdominant HLA-A*0201-restricted T-cell epitopes of HBx antigen of hepatitis B virus (Microbes and Infection 7 (2005) 626-634). [cited by applicant]
Zheng et al., “In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein”, VIRUSES, vol. 9, No. 5, Jan. 1, 2017 (Jan. 1, 2017), p. 112, XP055690912, CH ISSN: 1999-4915, DOI: 10.… [cited by applicant]
Malmassari et al: “In vivo hierarchy of immunodominant and subdominant HLA-A*0201-restricted T-cell epitopes of HBx antigen of hepatitis B virus”, Microbes and Infection, Elsevier, Paris, FR, vol. 7, No. 4, Apr. 1, 2005… [cited by applicant]